Patent litigation attorney
Justin T. Fleischacker
3 tracked appearances — 0 plaintiff · 3 defendant.
Specialty & background
Let me verify outcomes for the prominent matters.
Let me verify a few remaining details.
Justin T. Fleischacker — Paul Hastings LLP (New York)
Specialty / focus. Fleischacker is a litigation associate whose practice centers on life sciences patent disputes — pharmaceuticals (including Hatch-Waxman ANDA and 505(b)(2) actions), biotechnology/biologics, and medical devices. His firm bio states the focus as "complex patent litigation with an emphasis on pharmaceuticals, medical devices and biotechnology," which is consistent with the tracked matters and with his technical background (B.S.E. in biomedical engineering). His docket record reflects small-molecule formulation and injectable-emulsion work (aprepitant/CINVANTI, Lenvima, Gocovri), antibody-drug conjugate biologics, and post-grant challenges to pharmaceutical patents. Nothing in the record shows Wi-Fi/standards-essential, software, or mechanical-arts work.
Side preference. The three tracked appearances are all defendant-side, all at Paul Hastings, and all as back-up counsel (one of those admitted pro hac vice). In practice he works for branded life sciences companies: he has appeared for patent owners/brand plaintiffs in ANDA litigation (Heron Therapeutics, Eisai, Adamas, Heron v. Slayback/Azurity in D.N.J. and D. Del.) and for accused infringers (Daiichi Sankyo against Seagen; Helsinn as defendant/patent owner in Azurity Pharmaceuticals v. Helsinn). There is no indication of NPE/PAE-side or plaintiff's-bar work; the "0 plaintiff / 3 defendant" split reflects a small tracked sample rather than a strict defense-only practice.
Firm context. He has been at Paul Hastings since at least 2020 (earliest tracked appearance, Seagen v. Daiichi Sankyo, E.D. Tex., Oct. 2020) and is based in the firm's New York office. No prior law-firm history was found in public sources; his pre-law-school employment was at a medical device company, where he is a named inventor on issued defibrillator-technology patents.
Notable matters. Seagen Inc. v. Daiichi Sankyo is the most significant — Paul Hastings represented Daiichi, and the Federal Circuit's Dec. 2, 2025 precedential decision (Nos. 2023-2424, 2024-1176) reversed the E.D. Tex. jury verdict and held Seagen's ADC patent (U.S. 10,808,039) invalid for lack of written description and enablement, vacating the willful-infringement finding and the ~$41.8M damages award; the companion PGR appeal (24-1878) was dismissed as moot. The same client relationship produced a reported $47M attorneys' fee award in an ADC-related arbitration. For Heron Therapeutics he was on the team that won the Dec. 3, 2024 D. Del. decision upholding CINVANTI patents '229 and '794 against Fresenius Kabi. Note that Heron later lost a related CINVANTI action against Azurity/Slayback (Judge Bryson invalidated '255 and '520 on June 1, 2026; on appeal), and other firm-listed results (Adamas/Sandoz, Eisai/Sun, Eisai/Merck v. Shilpa) are described by the firm as settlements or trial wins — I could not independently verify his individual role in each.
PTAB / IPR. He has substantial post-grant exposure but appears in a supporting, non-lead capacity. He was admitted pro hac vice as back-up counsel only — three related Helsinn IPRs (IPR2025-00945, -00946, -00948, involving U.S. Patents 8,623,826, 9,186,357 and 9,943,515) — by Board orders dated Jan. 13, 2026, and his declaration in that proceeding stated he had not applied for pro hac vice admission in any other Office proceeding in the prior three years. His PTAB work has otherwise been behind registered lead counsel, and he is not identified in the record as a registered patent practitioner.
Bar / education. Admitted in New York; J.D. cum laude, Benjamin N. Cardozo School of Law (2018, IP concentration, Cardozo Law Review articles editor); B.S.E., University of Connecticut (2015). Recognized in Best Lawyers: Ones to Watch for IP law, life sciences, and patent litigation since 2024.
Sources: Paul Hastings attorney profile; USPTO/PTAB filings and Board decisions in IPR2025-00945/-00946/-00948; Federal Circuit opinions in Seagen v. Daiichi Sankyo (2023-2424, 2024-1878); D. Del. and D.N.J. dockets in the Heron Therapeutics matters; Heron and Fresenius press releases; Best Lawyers profile; Law360 attorney page.
Firms
Roles
- back-up counsel2
- back-up counsel, pro hac vice1
Cases (3)
- Δ defendantAzurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.Paul Hastings · back-up counsel
- Δ defendantAzurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.Paul Hastings · back-up counsel, pro hac vice
- Δ defendantAzurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.Paul Hastings · back-up counsel